Onkologie. 2017:11(2):96-98 | DOI: 10.36290/xon.2017.020

kolorektální karcinom, metastáza, chemoterapie, bevacizumab, resekce metastáz

Věra Benešová

Onkologické oddělení, Nemocnice Jihlava

Colorectal cancer (C18-20) is the second leading malignancy in women as well as men. Its incidence has been rising constantly and the good news is that, in the recent years, its mortality has been declining slowly, which can be, in part, caused by the introduction of a screening programme (www.kolorektum.cz). On the contrary, the bad news is that as many as 20 % of patients with a primary diagnosis of colorectal cancer are found to have metastatic involvement. In another 20 to 30 % of patients, metastases occur within the subsequent two years. In patients with the presence of liver metastatic foci, the option of resecting these foci always has to be considered. In case a radical resection of liver metastases is performed, it results in significant increase in survival. In treating metastatic colorectal cancer disease, it is therefore important to determine the course of treatment in a multidisciplinary team and to thoroughly plan the individual therapy sequences. The present case report describes the treatment of metastatic colorectal cancer and highlights the importance of interdisciplinary coordination in improving treatment outcomes.

Keywords: colorectal cancer, metastasis, chemotherapy, bevacizumab, metastasis resection

Published: May 1, 2017  Show citation